Anti-IgE therapy with omalizumab has raised concerns of an increased risk of arterial thrombotic events, particularly myocardial infarction (MI) and stroke74, conditions that have also been associated with A1AT deficiency (reviewed in75). Here, SERPINA1 is linked to hyperinsulinemic hypoglycemia, familial, 4.